Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

Impact of diet on irinotecan toxicity in mice.

Mallick P, Shah P, Ittmann MM, Trivedi M, Hu M, Gao S, Ghose R.

Chem Biol Interact. 2018 Jun 18;291:87-94. doi: 10.1016/j.cbi.2018.06.018. [Epub ahead of print]

PMID:
29913120
2.

TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis.

Singh R, Karri D, Shen H, Shao J, Dasgupta S, Huang S, Edwards DP, Ittmann MM, O'Malley BW, Yi P.

J Clin Invest. 2018 Jun 18. pii: 96060. doi: 10.1172/JCI96060. [Epub ahead of print]

3.

Fibroblast growth factor receptor signaling plays a key role in transformation induced by the TMPRSS2/ERG fusion gene and decreased PTEN.

Shao L, Wang J, Karatas OF, Feng S, Zhang Y, Creighton CJ, Ittmann M.

Oncotarget. 2018 Feb 12;9(18):14456-14471. doi: 10.18632/oncotarget.24470. eCollection 2018 Mar 6.

4.

Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases.

Chen F, Zhang Y, Gibbons DL, Deneen B, Kwiatkowski DJ, Ittmann M, Creighton CJ.

Clin Cancer Res. 2018 May 1;24(9):2182-2193. doi: 10.1158/1078-0432.CCR-17-3378. Epub 2018 Feb 9.

PMID:
29440175
5.

Influence of the neural microenvironment on prostate cancer.

Coarfa C, Florentin D, Putluri N, Ding Y, Au J, He D, Ragheb A, Frolov A, Michailidis G, Lee M, Kadmon D, Miles B, Smith C, Ittmann M, Rowley D, Sreekumar A, Creighton CJ, Ayala G.

Prostate. 2018 Feb;78(2):128-139. doi: 10.1002/pros.23454. Epub 2017 Nov 13.

6.

Anatomy and Histology of the Human and Murine Prostate.

Ittmann M.

Cold Spring Harb Perspect Med. 2018 May 1;8(5). pii: a030346. doi: 10.1101/cshperspect.a030346. Review.

PMID:
29038334
7.

Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.

Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Ittmann M, Schweizer M, True LD, Wise D, Rennie PS, Vessella RL, Morrissey C, Nelson PS.

Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003.

PMID:
29017058
8.

miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer.

Karatas OF, Wang J, Shao L, Ozen M, Zhang Y, Creighton CJ, Ittmann M.

Oncotarget. 2017 Jul 24;8(36):60243-60256. doi: 10.18632/oncotarget.19521. eCollection 2017 Sep 1.

9.

Pan-urologic cancer genomic subtypes that transcend tissue of origin.

Chen F, Zhang Y, Bossé D, Lalani AA, Hakimi AA, Hsieh JJ, Choueiri TK, Gibbons DL, Ittmann M, Creighton CJ.

Nat Commun. 2017 Aug 4;8(1):199. doi: 10.1038/s41467-017-00289-x.

10.

RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression.

Wang Y, Wang J, Zhang L, Karatas OF, Shao L, Zhang Y, Castro P, Creighton CJ, Ittmann M.

Cancer Res. 2017 Aug 15;77(16):4247-4257. doi: 10.1158/0008-5472.CAN-17-0669. Epub 2017 Jun 13.

PMID:
28611045
11.

Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.

Moss TJ, Qi Y, Xi L, Peng B, Kim TB, Ezzedine NE, Mosqueda ME, Guo CC, Czerniak BA, Ittmann M, Wheeler DA, Lerner SP, Matin SF.

Eur Urol. 2017 Oct;72(4):641-649. doi: 10.1016/j.eururo.2017.05.048. Epub 2017 Jun 7.

PMID:
28601352
12.

Expression of pattern recognition receptor genes and mortality in patients with colorectal adenocarcinoma.

Royse KE, Chen L, Berger DH, Ittmann MM, El-Serag HB, Balentine CJ, Graham DY, Richardson PA, Rumbaut RE, Shen X, White DL, Jiao L.

Int J Mol Epidemiol Genet. 2017 Apr 15;8(2):8-18. eCollection 2017.

13.

A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.

Zhang Y, Kwok-Shing Ng P, Kucherlapati M, Chen F, Liu Y, Tsang YH, de Velasco G, Jeong KJ, Akbani R, Hadjipanayis A, Pantazi A, Bristow CA, Lee E, Mahadeshwar HS, Tang J, Zhang J, Yang L, Seth S, Lee S, Ren X, Song X, Sun H, Seidman J, Luquette LJ, Xi R, Chin L, Protopopov A, Westbrook TF, Shelley CS, Choueiri TK, Ittmann M, Van Waes C, Weinstein JN, Liang H, Henske EP, Godwin AK, Park PJ, Kucherlapati R, Scott KL, Mills GB, Kwiatkowski DJ, Creighton CJ.

Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.

14.

RET Signaling in Prostate Cancer.

Ban K, Feng S, Shao L, Ittmann M.

Clin Cancer Res. 2017 Aug 15;23(16):4885-4896. doi: 10.1158/1078-0432.CCR-17-0528. Epub 2017 May 10.

PMID:
28490466
15.

A Versatile Tumor Gene Deletion System Reveals a Crucial Role for FGFR1 in Breast Cancer Metastasis.

Wang W, Meng Y, Dong B, Dong J, Ittmann MM, Creighton CJ, Lu Y, Zhang H, Shen T, Wang J, Rowley DR, Li Y, Chen F, Moore DD, Yang F.

Neoplasia. 2017 May;19(5):421-428. doi: 10.1016/j.neo.2017.03.003. Epub 2017 Apr 20.

16.

SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.

Geng C, Kaochar S, Li M, Rajapakshe K, Fiskus W, Dong J, Foley C, Dong B, Zhang L, Kwon OJ, Shah SS, Bolaki M, Xin L, Ittmann M, O'Malley BW, Coarfa C, Mitsiades N.

Oncogene. 2017 Aug 17;36(33):4767-4777. doi: 10.1038/onc.2017.80. Epub 2017 Apr 17.

17.

Cellular interactions of the phosphorylated form of AKT in prostate cancer.

Hammerich KH, Frolov A, Li R, Ittmann M, Ayala GE.

Hum Pathol. 2017 May;63:98-109. doi: 10.1016/j.humpath.2017.02.014. Epub 2017 Mar 11.

PMID:
28300578
18.

SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.

Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, Nataraj S, Deonarine LD, Augello MA, Sailer V, Ponnala L, Ittmann M, Chinnaiyan AM, Sboner A, Chen Y, Rubin MA, Barbieri CE.

Cancer Cell. 2017 Mar 13;31(3):436-451. doi: 10.1016/j.ccell.2017.02.004.

19.

Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.

Feng S, Shao L, Castro P, Coleman I, Nelson PS, Smith PD, Davies BR, Ittmann M.

Oncotarget. 2017 Jan 24;8(4):6179-6192. doi: 10.18632/oncotarget.14049.

20.

CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT.

Chaudhury A, Cheema S, Fachini JM, Kongchan N, Lu G, Simon LM, Wang T, Mao S, Rosen DG, Ittmann MM, Hilsenbeck SG, Shaw CA, Neilson JR.

Nat Commun. 2016 Nov 21;7:13362. doi: 10.1038/ncomms13362.

21.

Identification of microRNA profile specific to cancer stem-like cells directly isolated from human larynx cancer specimens.

Karatas OF, Suer I, Yuceturk B, Yilmaz M, Oz B, Guven G, Cansiz H, Creighton CJ, Ittmann M, Ozen M.

BMC Cancer. 2016 Nov 5;16(1):853.

22.

MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer.

Zhang L, Wang J, Wang Y, Zhang Y, Castro P, Shao L, Sreekumar A, Putluri N, Guha N, Deepak S, Padmanaban A, Creighton CJ, Ittmann M.

Cancer Res. 2016 Nov 1;76(21):6290-6298. Epub 2016 Aug 30.

23.

The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors.

Zhang Z, Lanz RB, Xiao L, Wang L, Hartig SM, Ittmann MM, Feng Q, He B.

Oncotarget. 2016 Jun 21;7(25):37993-38003. doi: 10.18632/oncotarget.9366.

24.

Positive association of collagen type I with non-muscle invasive bladder cancer progression.

Brooks M, Mo Q, Krasnow R, Ho PL, Lee YC, Xiao J, Kurtova A, Lerner S, Godoy G, Jian W, Castro P, Chen F, Rowley D, Ittmann M, Chan KS.

Oncotarget. 2016 Dec 13;7(50):82609-82619. doi: 10.18632/oncotarget.12089.

25.

Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor.

Zhang B, Kwon OJ, Henry G, Malewska A, Wei X, Zhang L, Brinkley W, Zhang Y, Castro PD, Titus M, Chen R, Sayeeduddin M, Raj GV, Mauck R, Roehrborn C, Creighton CJ, Strand DW, Ittmann MM, Xin L.

Mol Cell. 2016 Sep 15;63(6):976-89. doi: 10.1016/j.molcel.2016.07.025. Epub 2016 Sep 1.

26.

Neuronal Trans-Differentiation in Prostate Cancer Cells.

Farach A, Ding Y, Lee M, Creighton C, Delk NA, Ittmann M, Miles B, Rowley D, Farach-Carson MC, Ayala GE.

Prostate. 2016 Oct;76(14):1312-25. doi: 10.1002/pros.23221. Epub 2016 Jul 12.

27.

A Versatile Gene Delivery System for Efficient and Tumor Specific Gene Manipulation in vivo.

Wang W, Dong B, Ittmann MM, Yang F.

Discoveries (Craiova). 2016 Apr-Jun;4(2). pii: e58. Epub 2016 Jun 22.

28.

The essential role of GATA transcription factors in adult murine prostate.

Xiao L, Feng Q, Zhang Z, Wang F, Lydon JP, Ittmann MM, Xin L, Mitsiades N, He B.

Oncotarget. 2016 Jul 26;7(30):47891-47903. doi: 10.18632/oncotarget.10294.

29.

Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer.

Su Q, Zhang B, Zhang L, Dang T, Rowley D, Ittmann M, Xin L.

Oncogene. 2017 Feb 2;36(5):618-627. doi: 10.1038/onc.2016.232. Epub 2016 Jun 27.

30.

Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model.

Kwon OJ, Zhang L, Wang J, Su Q, Feng Q, Zhang XH, Mani SA, Paulter R, Creighton CJ, Ittmann MM, Xin L.

J Clin Invest. 2016 Jul 1;126(7):2626-41. doi: 10.1172/JCI84637. Epub 2016 Jun 13.

31.

The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker.

Xiao L, Lanz RB, Frolov A, Castro PD, Zhang Z, Dong B, Xue W, Jung SY, Lydon JP, Edwards DP, Mancini MA, Feng Q, Ittmann MM, He B.

Prostate. 2016 Oct;76(14):1271-84. doi: 10.1002/pros.23213. Epub 2016 Jun 8.

PMID:
27272765
32.

Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer.

Kaushik AK, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnan H, Manikkam M, Zaslavsky A, Putluri V, Vasu VT, Zhang Y, Khan AS, Lloyd S, Szafran AT, Dasgupta S, Bader DA, Stossi F, Li H, Samanta S, Cao X, Tsouko E, Huang S, Frigo DE, Chan L, Edwards DP, Kaipparettu BA, Mitsiades N, Weigel NL, Mancini M, McGuire SE, Mehra R, Ittmann MM, Chinnaiyan AM, Putluri N, Palapattu GS, Michailidis G, Sreekumar A.

Nat Commun. 2016 May 19;7:11612. doi: 10.1038/ncomms11612.

33.

GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells.

Sang M, Hulsurkar M, Zhang X, Song H, Zheng D, Zhang Y, Li M, Xu J, Zhang S, Ittmann M, Li W.

Oncotarget. 2016 Jul 19;7(29):45171-45185. doi: 10.18632/oncotarget.9359.

34.

Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer.

Lin SC, Kao CY, Lee HJ, Creighton CJ, Ittmann MM, Tsai SJ, Tsai SY, Tsai MJ.

Nat Commun. 2016 Apr 25;7:11418. doi: 10.1038/ncomms11418.

35.

Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B.

Woodfield SE, Guo RJ, Liu Y, Major AM, Hollingsworth EF, Indiviglio S, Whittle SB, Mo Q, Bean AJ, Ittmann M, Lopez-Terrada D, Zage PE.

Genes Cancer. 2016 Jan;7(1-2):13-26.

36.

Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression.

Lopez SM, Agoulnik AI, Zhang M, Peterson LE, Suarez E, Gandarillas GA, Frolov A, Li R, Rajapakshe K, Coarfa C, Ittmann MM, Weigel NL, Agoulnik IU.

Clin Cancer Res. 2016 Aug 1;22(15):3937-49. doi: 10.1158/1078-0432.CCR-15-1983. Epub 2016 Mar 11.

37.

A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation.

Whittle SB, Reyes S, Du M, Gireud M, Zhang L, Woodfield SE, Ittmann M, Scheurer ME, Bean AJ, Zage PE.

J Pediatr Hematol Oncol. 2016 Mar;38(2):131-8. doi: 10.1097/MPH.0000000000000506.

38.

Functional annotation of rare gene aberration drivers of pancreatic cancer.

Tsang YH, Dogruluk T, Tedeschi PM, Wardwell-Ozgo J, Lu H, Espitia M, Nair N, Minelli R, Chong Z, Chen F, Chang QE, Dennison JB, Dogruluk A, Li M, Ying H, Bertino JR, Gingras MC, Ittmann M, Kerrigan J, Chen K, Creighton CJ, Eterovic K, Mills GB, Scott KL.

Nat Commun. 2016 Jan 25;7:10500. doi: 10.1038/ncomms10500.

39.

Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation.

Gingras MC, Covington KR, Chang DK, Donehower LA, Gill AJ, Ittmann MM, Creighton CJ, Johns AL, Shinbrot E, Dewal N, Fisher WE; Australian Pancreatic Cancer Genome Initiative, Pilarsky C, Grützmann R, Overman MJ, Jamieson NB, Van Buren G 2nd, Drummond J, Walker K, Hampton OA, Xi L, Muzny DM, Doddapaneni H, Lee SL, Bellair M, Hu J, Han Y, Dinh HH, Dahdouli M, Samra JS, Bailey P, Waddell N, Pearson JV, Harliwong I, Wang H, Aust D, Oien KA, Hruban RH, Hodges SE, McElhany A, Saengboonmee C, Duthie FR, Grimmond SM, Biankin AV, Wheeler DA, Gibbs RA.

Cell Rep. 2016 Feb 2;14(4):907-919. doi: 10.1016/j.celrep.2015.12.005. Epub 2016 Jan 21.

40.

Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties.

Paranjape AN, Soundararajan R, Werden SJ, Joseph R, Taube JH, Liu H, Rodriguez-Canales J, Sphyris N, Wistuba I, Miura N, Dhillon J, Mahajan N, Mahajan K, Chang JT, Ittmann M, Maity SN, Logothetis C, Tang DG, Mani SA.

Oncogene. 2016 Nov 17;35(46):5963-5976. doi: 10.1038/onc.2015.498. Epub 2016 Jan 25.

41.

Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations.

Bianchi-Frias D, Basom R, Delrow JJ, Coleman IM, Dakhova O, Qu X, Fang M, Franco OE, Ericson NG, Bielas JH, Hayward SW, True L, Morrissey C, Brown L, Bhowmick NA, Rowley D, Ittmann M, Nelson PS.

Mol Cancer Res. 2016 Apr;14(4):374-84. doi: 10.1158/1541-7786.MCR-15-0330. Epub 2016 Jan 11.

42.

The role of ATP-binding cassette transporter genes in the progression of prostate cancer.

Karatas OF, Guzel E, Duz MB, Ittmann M, Ozen M.

Prostate. 2016 Apr;76(5):434-44. doi: 10.1002/pros.23137. Epub 2015 Dec 28.

PMID:
26708806
43.

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R.

N Engl J Med. 2016 Jan 14;374(2):135-45. doi: 10.1056/NEJMoa1505917. Epub 2015 Nov 4.

44.

The role of miR-145 in stem cell characteristics of human laryngeal squamous cell carcinoma Hep-2 cells.

Karatas OF, Suer I, Yuceturk B, Yilmaz M, Hajiyev Y, Creighton CJ, Ittmann M, Ozen M.

Tumour Biol. 2016 Mar;37(3):4183-92. doi: 10.1007/s13277-015-4219-z. Epub 2015 Oct 22.

PMID:
26490990
45.

Oxidative stress promotes benign prostatic hyperplasia.

Vital P, Castro P, Ittmann M.

Prostate. 2016 Jan;76(1):58-67. doi: 10.1002/pros.23100. Epub 2015 Sep 29.

46.

Role of miR-145 in human laryngeal squamous cell carcinoma.

Karatas OF, Yuceturk B, Suer I, Yilmaz M, Cansiz H, Solak M, Ittmann M, Ozen M.

Head Neck. 2016 Feb;38(2):260-6. doi: 10.1002/hed.23890. Epub 2015 Jun 16.

PMID:
26083661
47.

Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors.

Szwarc MM, Kommagani R, Jacob AP, Dougall WC, Ittmann MM, Lydon JP.

PLoS One. 2015 Jun 10;10(6):e0128467. doi: 10.1371/journal.pone.0128467. eCollection 2015.

48.

FGF23 promotes prostate cancer progression.

Feng S, Wang J, Zhang Y, Creighton CJ, Ittmann M.

Oncotarget. 2015 Jul 10;6(19):17291-301.

49.

Expression of ERG protein in prostate cancer: variability and biological correlates.

Ayala G, Frolov A, Chatterjee D, He D, Hilsenbeck S, Ittmann M.

Endocr Relat Cancer. 2015 Jun;22(3):277-87. doi: 10.1530/ERC-14-0586.

50.

Overexpression of miR-145-5p inhibits proliferation of prostate cancer cells and reduces SOX2 expression.

Ozen M, Karatas OF, Gulluoglu S, Bayrak OF, Sevli S, Guzel E, Ekici ID, Caskurlu T, Solak M, Creighton CJ, Ittmann M.

Cancer Invest. 2015 Jul;33(6):251-8. doi: 10.3109/07357907.2015.1025407. Epub 2015 May 7.

PMID:
25951106

Supplemental Content

Loading ...
Support Center